Home / Health / Novo Nordisk Halves Drug Prices for US Market
Novo Nordisk Halves Drug Prices for US Market
24 Feb
Summary
- Novo Nordisk will reduce US list prices for Wegovy and Ozempic.
- The price reduction for these blockbuster drugs will be up to 50%.
- These changes are set to take effect starting in 2027.
Starting in 2027, Novo Nordisk plans to substantially decrease the U.S. list prices for its widely recognized diabetes and weight-loss drugs, Ozempic and Wegovy. The Danish pharmaceutical company stated that these price reductions could reach as high as 50%.
This significant policy change will impact two of Novo Nordisk's most successful medications. The company's decision to halve the prices of these blockbuster drugs in the American market is expected to improve patient access.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
